300 results about "Cardiac disorders" patented technology

The invention discloses an electrocardiogram classification system and method fusing multi-scale self-adaptive attention, and relates to the technical field of electrocardiogram classification.The electrocardiogram classification method comprises the steps that electrocardiogram data are collected through a data collection module, and a structured data set is output; the data preprocessing module is used for carrying out data preprocessing on the structured data set; the window data segmentation module obtains a standardized windowed electrocardiosignal; the feature extraction module takes the standardized windowed electrocardiosignals as input, performs three stages of multi-scale convolution feature extraction, liquid neural network dynamic modeling and self-adaptive attention mechanism enhancement, and outputs diagnosis results of nine types of heart diseases; and the training and optimizing module is used for optimizing the extraction and classification capability of the model on the electrocardiosignal features, so that the technical effects of full-process technical upgrading from data acquisition, preprocessing, feature extraction to model training optimization and high-precision electrocardiogram automatic classification are achieved.

The invention relates to the technical field of heart data analysis, in particular to an AI (artificial intelligence)-based heart disease prediction system, which comprises a feature relationship modeling module for mapping each type of information into a multi-dimensional feature space based on collected heart data, analyzing the condition correlation degree between feature nodes, connecting the feature nodes through correlation information, and establishing a model; and quantifying a linkage effect between the features to obtain a feature condition dependency relationship analysis result. According to the method, various types of heart health data are noded by constructing a multi-dimensional feature space, and a correlation structure is established according to condition correlation among data features. And a synergistic effect and an interdependence relationship among the features are disclosed. By analyzing the joint state probability of the feature nodes, the linkage effect of the feature combination on the overall risk is quantified, and the analysis depth of the disease risk is enhanced. In addition, by comparing the independent state probability of a single feature with the joint state probability of the feature combination, a feature combination that makes a significant contribution to the risk can be identified.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Embodiments herein provide a system and method for screening and monitoring of cardiac diseases by analyzing acquired physiological signals. Unlike state of art approaches that consider only synchronized ECG and PPG signals for cardiac health analysis and do not consider PCG which is a critical signal for CAD analysis, the system synchronously captures physiological signals such as photo plethysmograph (PPG), phonocardiogram (PCG) and electrocardiogram (ECG) from subject(s) and builds an analytical model in the cloud for analyzing heart conditions from the captured physiological signals. The system and method provides a fusion based approach of combining the captured physiological signals such as PPG, PCG and ECG along with other details such as subject clinical information, demography information and so on. The analytical model is pretrained using ECG. PPG and PCG along with metadata associated with the subject such as demography and clinical information.

The invention discloses a piRNA marker for diagnosing and evaluating myocardial aging, a kit and application of the piRNA marker. The application of the miRNA marker comprises one or more of the following applications: A1) application in preparation of a product for diagnosing myocardial aging; a2) in preparation of products for screening myocardial aging; a3) in preparation of a product for treating myocardial aging; a4) in preparation of myocardial aging condition assessment products; a5) in preparation of products for identifying and distinguishing myocardial aging and other heart diseases; the piRNA marker is piR-hsa-014388, and the nucleotide sequence of the piRNA marker is as shown in SEQ ID No. 1. The expression quantity of the piRNA marker provided by the invention in the plasma of a myocardial aging patient is obviously increased compared with that of a healthy control person, which indicates that the piR-hsa-014388 has the potential to be used as the myocardial aging biomarker.

The invention discloses a multi-mode-based flexible wearable heart function monitoring method, system and device, and relates to the technical field of health monitoring, and the method comprises the steps: outputting a multi-mode signal through a flexible patch sensing module when the flexible patch sensing module is arranged in a detection area; wherein the flexible patch sensing module comprises an electrocardio sensor, a pulse wave sensor, a heart sound sensor, a strain sensor and a microfluidic biosensor. According to the invention, high-precision synchronous signal acquisition is realized through flexible patch integrated multi-modal sensing, heart multi-source signal features are adaptively extracted in combination with a multi-scale convolutional neural model, and timing sequence relevance is captured by using a bidirectional long-short-term memory network, so that the accuracy and reliability of heart disease diagnosis are remarkably improved, and the accuracy and reliability of heart disease diagnosis are improved. Meanwhile, non-invasive and continuous monitoring and early pathological screening are supported.

The invention provides a heart electro-mechanical coupling cross-modal time-space-semantic alignment method, which comprises the following steps: acquiring a multi-modal medical data set, and performing spatial registration on the multi-modal medical data set through a dynamic mapping matrix constructed based on a deformable convolutional network to obtain a spatial coupling medical data set; performing time sequence synchronization on the space coupling medical data set based on a double-flow time convolution network to obtain a space-time coupling medical data set; performing cross-modal pathological semantic alignment on the space-time coupling medical data set through a prototype semantic contrast learning framework to obtain a space-time-semantic alignment data set; and data mining is performed on the space-time-semantic alignment data set based on a triple sparse cross attention mechanism to obtain fusion features, and the fusion features are used for quantifying the importance of each data in the space-time-semantic alignment data set. By adopting the method, cross-modal space-time consistency alignment and semantic calibration can be realized, so that the heart disease pathology association mining capability and the intelligent diagnosis accuracy are improved.

The invention discloses application of fisetin or a salt thereof in medicine preparation, the compound is used for treating or preventing obesity cardiomyopathy, preferably heart diseases caused by hyperlipidemia, but is not limited to the inducer, and specifically, the medicine can inhibit or improve various obesity cardiomyopathy.

The invention relates to a three-dimensional electrocardio scatter diagram analysis method and device based on heart rate variability and a medium, and relates to the technical field of biomedical signal processing. According to the method, the heart rate data of the user can be mapped into the three-dimensional points in the three-dimensional coordinate system after being preprocessed, the coordinate axes of the three-dimensional coordinate system are the time domain index, the frequency domain index and the nonlinear index, the heart rate change is displayed from three dimensions, compared with a traditional two-dimensional scatter diagram, the heart rate change characteristics can be more comprehensively and stereoscopically displayed, and the user experience is improved. According to the method, more potential heart disease related information is captured, heart rate data features are deeply excavated by constructing a three-dimensional electrocardiogram scatter diagram containing more heart rate change information, heart rate scatter indexes are quantified, and risk levels of heart diseases such as arrhythmia and atrial fibrillation are scientifically and accurately evaluated according to the scatter indexes. And the accuracy and reliability of heart disease risk assessment are improved.

The invention relates to an electrocardiogram monitoring method and device, a storage medium and electronic equipment, and relates to the technical field of electrocardiogram, and the method comprises the following steps: obtaining a target portrait of a to-be-monitored user; according to the target portrait, determining at least one suitable fitting part during electrocardiogram monitoring; determining an actual electrocardiogram of the to-be-monitored user based on each suitable fitting part, and judging whether the actual electrocardiogram is an abnormal electrocardiogram or not; if yes, acquiring actual symptoms of the to-be-monitored user, and determining whether the to-be-monitored user has a heart disease hidden danger or not based on the actual symptoms, target heart problems easily occurring when the electrocardiogram of the to-be-monitored user is abnormal and easily accompanied symptoms corresponding to each target heart problem; if it is determined that the heart disease hidden danger exists, targeted heart disease early warning is sent out. The method has the effect of improving the accuracy of electrocardiogram monitoring.

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and / or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

The invention discloses an integral forming method of a myocardial chip embedded with nanofibers and a flexible circuit board, which adopts integral forming equipment, integrates a photocuring part and an electrostatic spinning part, and realizes collaborative operation through an upper computer and a driving device; the method comprises the following steps: firstly, forming a lower runner layer by adopting a hydrogel material through a photocuring component, and embedding a flexible circuit board into the top of the lower runner layer; forming a nanofiber bracket on the flexible circuit board by adopting a spinning material through the electrostatic spinning part; a hydrogel material is printed on the nanofiber support to form an upper flow channel layer, flow channel packaging is achieved, and efficient transmission of electrical stimulation and field potential signals is achieved through a flexible circuit board. According to the method, the problems of low alignment precision, strong manual dependence and insufficient automation degree in the traditional process are solved, the chip manufacturing efficiency and consistency are improved, and a detection platform with high integration level and high biocompatibility is provided for drug screening and heart disease research.

The present technology relates to modular valve replacement systems for treating valve-related cardiac disorders. In select embodiments, the modular valve replacement system includes a fixation device and a permanent valve assembly. The fixation device and the permanent valve assembly are delivered separately, enabling use of smaller delivery systems and facilitating less-invasive implant techniques. The fixation device is implanted first and provides a mounting fixture for the subsequently delivered permanent valve assembly. In some embodiments, the permanent valve assembly is at least partially mechanically isolated from the fixation device after the permanent valve assembly is attached to the fixation device. In some embodiments, the fixation device includes a temporary valve assembly that prevents regurgitation until the permanent valve assembly is implanted.

The invention provides a heart-targeted nano-liposome delivery carrier, a circular RNA (Ribonucleic Acid) medicine for treating cardiovascular diseases as well as a preparation method and application of the circular RNA medicine, and belongs to the technical field of biomedicine. The heart-targeted nano-liposome delivery carrier comprises saccular nano-liposome particles and heart-targeted peptide CMP (chemical mechanical polishing) modified on the surfaces of the nano-liposome particles, the amino acid sequence of the heart targeting peptide CMP is shown as SEQ ID NO: 6. The heart-targeted nano-liposome delivery carrier has a good heart-targeted effect, and the nano-liposome delivery carrier is used as a delivery tool to accurately deliver a circular RNA drug to a heart part, so that the effect of treating cardiovascular diseases (such as cardiac hypertrophy) is greatly improved; a new treatment mode is provided for clinical treatment of cardiovascular diseases, and the purpose of efficiently preventing and treating heart diseases is achieved.

The invention discloses a pyrimidinedione derivative as well as a preparation method and application thereof. Molecules of the pyrimidinedione derivative have better myosin inhibitory activity, also have antioxidant effects of DPPH and / or MDA and the like and anti-ferroptosis activity, and can be applied to treatment / prevention of heart myosin, anti-oxidative stress and anti-ferroptosis mechanism related diseases. The diseases or symptoms mainly comprise hypertrophic cardiomyopathy, diastolic heart failure, left ventricular hypertrophy, heart diseases with pathophysiological characteristics related to the hypertrophic cardiomyopathy, or other disease states and conditions which are obvious to those skilled in the art, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof, and a pharmaceutical composition containing the same.

The invention provides a hierarchical multi-modal heart data completion method based on double knowledge guidance, which comprises the following steps: S1, extracting complete multi-modal joint features from complete multi-modal data through a teacher network, and carrying out cross-sample comparative learning and dynamic feature fusion on missing modal data through a student network to obtain a multi-modal data fusion model; generating completion features containing individual specific information; s2, based on the completion features, constructing a category prototype vector of the heart disease subtype, and generating semantic constraints representing disease subtype rules through prototype perception comparison distillation and moving average evolutionary strategies; s3, the complementation features and the semantic constraints are combined, network parameters and prototype vectors are optimized through back propagation iteration, complementation data are generated, and the complementation data comprise individual electrophysiological features and pathological subtype marks. By adopting the method, the individual specificity and the pathological evolution rule can be considered, and the reconstruction data can be ensured to meet the accurate heart disease diagnosis requirement at the same time.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a heart-benefiting natural plant preparation for pets and a preparation method of the heart-benefiting natural plant preparation. The heart-benefiting natural plant preparation comprises the following components: astragalus membranaceus, ginseng, lucid ganoderma, honey-fried licorice root, salvia miltiorrhiza, auxiliary materials, platycodon grandiflorum, medlar, pueraria flower, smoked plum, coix seed and rhizoma alismatis. The natural plant preparation is prepared by adding platycodon grandiflorum, medlar, kudzuvine root flower, smoked plum, coix seed and rhizoma alismatis into the designed pet medicine, and the platycodon grandiflorum, the medlar, the kudzuvine root flower, the smoked plum, the coix seed and the rhizoma alismatis are medicine and food homologous medicines and have good pharmacological effects; the traditional Chinese medicine composition can obviously control the rise of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase levels in serum during liver injury, can promote the rise of ADH and GSH-Px in liver tissues, and inhibits the rise of MDA, so that the liver protection effect is achieved, the conditions of increase of toxins in blood, rise of blood fat and the like caused by poor metabolism of substances which cannot be metabolized by liver due to liver function injury are avoided, and the traditional Chinese medicine composition can be used for treating liver injury. And then the blood enters the heart to circulate, so that the heart is injured to induce heart diseases.

The invention relates to the technical field of intelligent medical treatment, and mainly relates to a heart disease recognition system and method based on 12-lead electrocardiosignal HRV feature extraction, and the system comprises a 12-lead electrocardiosignal preprocessing module which is used for carrying out denoising preprocessing on electrocardiosignals; the heart rate variation HRV signal extraction module is used for extracting a heart rate variation HRV signal; the HRV feature rule mining and rule base construction module is used for mining HRV signal sequence features and generating a standard rule base; and the multi-classification heart disease identification module is used for classifying and identifying heart diseases. According to the system, the correlation between heart rate variation characteristics and various heart diseases is comprehensively considered, and the accuracy of heart disease recognition and classification is improved through matching calculation of the spectrum amplitude change sequence and the rule base. Moreover, the system is wide in applicability, and can effectively meet the recognition requirements of different types of heart diseases.

The invention provides an application of human source circular RNA hsacirc0083796 in preparation of a diagnostic reagent or a medicine for diagnosing and / or treating aortic dissection. The invention also provides a kit for diagnosing the aortic dissection. The invention also provides a pharmaceutical composition for treating aortic dissection. According to the application of the human source circular RNA in preparation of heart disease related products, the related heart disease related circular RNA (circled-Frizzled class receptor 3, hsacirc0083796) is one of circular RNAs with the highest expression quantity in the blood of aortic dissection patients and has high conservative property, the function of the circular RNA is closely related to heart diseases, and the circular RNA has a good application prospect in preparation of heart disease related products. The method has great significance in diagnosis and treatment of heart diseases. Meanwhile, due to the stable and specific properties of the circular RNA, compared with other types of markers, the circular RNA has larger abundance in body fluid of a patient and more obvious change, so that the circular RNA has the potential of becoming a novel diagnostic marker.

The invention discloses application of terpinenol compounds in preparation of medicines for treating heart diseases, in particular to preparation of medicines for resisting heart failure. After doxorubicin-induced chronic heart failure rat models are administered, the terpinenol compound can obviously increase the maximum rising rate and the maximum decreasing rate of left ventricular internal pressure in the doxorubicin-induced chronic heart failure rat models, increase the rat heart ejection fraction in the chronic heart failure rat models, relieve the heart hemodynamics of the chronic heart failure rats to a certain extent, and improve the curative effect of the doxorubicin-induced chronic heart failure rats. Experimental evidence is provided for clinical application of the terpinenol compound to treatment of heart failure, and the terpinenol compound has good application and development prospects.

The invention discloses a signal acquisition system of a self-adaptive film electrode patch for heart diseases, and relates to the technical field of medical instruments, the signal acquisition system comprises a flexible substrate, a nano electrode wire, an electrode patch and a circuit module; a bonding layer is arranged on the bottom surface of the flexible substrate, an anti-allergic medicine is distributed in the bonding layer, and the flexible substrate is used for being attached to the skin surface through the bonding layer; the plurality of nano electrode wires are distributed on the bonding layer of the flexible substrate, one ends of the plurality of nano electrode wires are respectively arranged at the detection points, the other ends of the plurality of electrode wires are connected with the circuit module, and the circuit module is used for outputting electric signals collected by the electrode paste; the electrode patch comprises a flexible conductive base layer and a contact layer, a printed circuit is arranged on one side of the flexible conductive base layer, the contact layer is attached to the printed circuit, the other side of the flexible conductive base layer is used for being bonded to a flexible substrate and located at a detection point, and the flexible conductive base layer is conducted with the nano electrode wire; the collection system is simple to operate, and solves the problems that an existing lead wire is easy to wind, the surgical field is affected, and skin allergy is caused by patch. The method has high use value and popularization value.

The invention provides a magnetic field simulation method based on electromechanical feedback of a real whole heart model. The method comprises the following steps: creating a real whole heart-trunk model containing various tissue structures of the heart; performing electrophysiology modeling based on the single-domain reaction diffusion model, and setting related parameters; coupling the electrophysiological model with the fiber direction and principal stress model, and solving transmembrane potential and mechanical shrinkage; and calculating a body surface magnetic field signal according to the transmembrane potential in combination with the current and magnetic field module. According to the invention, more real and accurate body surface magnetic field signal prediction can be provided, and the accuracy and efficiency of heart disease diagnosis can be improved.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Electrocardiography (ECG) data acquired from a subject and processed with a machine learning model to determine whether the subject has a particular cardiac condition, such as a cardiac arrhythmia, myocardial ischemia and / or myocardial infarction, or the like. The machine learning model generates classified feature data that are indicative of the presence and / or likelihood of a particular cardiac condition.

The present invention provides a bioluminescence probe for detecting norepinephrine, its preparation method and use, belonging to the field of biological detection. The bioluminescence probe of the present invention has high selectivity and high responsiveness to norepinephrine, can specifically recognize norepinephrine, has high sensitivity and low detection limit, and can be used for the precise detection of norepinephrine. In the range of pH 1.0 to 7.4, the bioluminescence probe of the present invention has excellent stability and can meet the application requirements under different physiological environments in vivo. At the same time, the norepinephrine bioluminescence probe of the present invention can also visually track exogenous norepinephrine at the in vivo level, and perform dynamic visual analysis on patients with diseases related to abnormal expression of norepinephrine involving nerves, tumors, blood pressure and heart diseases, which is beneficial to the clinical detection of norepinephrine and has broad application prospects.

The invention relates to the technical field of biological medicines, in particular to application of a monoclonal antibody in medicines for treating heart diseases related to Alzheimer's disease. According to the application disclosed by the invention, the application range of the lencanamazumab is expanded to prevention and treatment of AD-accompanied heart failure and pathological myocardial remodeling, and a new drug strategy is provided for treatment of patients with AD-associated heart failure or pathological myocardial remodeling.

The invention is directed to a miRNA with a RNA sequence comprising or consisting of hsa-miR-4784 with SEQ ID NO: 6, or a member of the miR-4784 family, or a primary transcript thereof, a precursor thereof, a mimic thereof or a combination for use as a medicament, preferably for use in treatment of a cardiac disease associated with loss of cardiac myocytes.

The invention discloses a traditional Chinese medicine atomizing agent with the effect of relieving heart diseases and a preparation method of the traditional Chinese medicine atomizing agent. The traditional Chinese medicine atomizing agent is prepared from the following traditional Chinese medicine raw materials: 3-10 g of ginseng, 4-15 g of pseudo-ginseng, 3-12 g of borneol, 8-15 g of ligusticum wallichii, 3-10 g of ginkgo leaves, 3-12 g of rohdea japonica roots, 2-6 g of venenum bufonis, 1-5 g of rhizoma curcumae longae, 5-8 g of long-noded pit viper and 10-15 g of mint. The selected traditional Chinese medicinal materials have the effects of promoting blood circulation to remove blood stasis, dredging channels and collaterals, tranquilizing mind by nourishing the heart and the like, the medicines rapidly enter the lung through the respiratory tract in an atomization mode and rapidly reach the heart through blood circulation, pertinence is high, rapid permeation and absorption of the medicines are achieved, the utilization rate of the medicines is increased, and the curative effect is rapidly exerted; the symptoms of patients with heart diseases are obviously improved, the body functions of the patients are regulated, and the recurrence rate of the diseases is reduced.